PARP inhibitors
ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer
The guideline comes in the wake of the OlympiA trial results, which showed that the PARP inhibitor significantly improved invasive disease-free survival.
Edison Oncology, Rakovina Therapeutics Partner on PARP Inhibitor Program
Edison has transferred ownership of its PARP inhibitor program to Rakovina in exchange for 43 percent of outstanding common shares in the firm.
Benefit of AstraZeneca's Cediranib Plus Lynparza May Be Limited to HRR-Deficient Prostate Cancers
Premium
According to a biomarker analysis from a Phase II trial, cediranib plus olaparib improved progression-free survival versus olaparib in HRR-deficient mCRPC.
SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach
Premium
With the PARIS test, researchers identified several targeted agents that could help patients overcome PARP inhibitor resistance and may be worth further study.
European Commission Green Lights Lynparza for Prostate, Ovarian Cancer Indications
Regulators approved the PARP inhibitor as a monotherapy for BRCA1/2-mutated mCRPC and together with Avastin for advanced, HRD-positive ovarian cancer.